Web Exclusives

At the 2017 Association of Community Cancer Centers Annual Meeting, Tricia Strusowski, RN, MS, Manager, Oncology Solutions, LLC, and project lead of the AONN+ Standardized Metrics Task Force, discussed how the newly released AONN+ Navigation Metrics can be incorporated into partnerships between oncology patient navigators and physician practices.

Emerging pharmacologic therapies used for the treatment of oncology are being developed and approved at an accelerated rate.

These results make quizartinib the first FLT3 inhibitor to demonstrate such improvement over chemotherapy in this patient population.

This infographic illustrates key findings from the first-of-its-kind study to examine outcomes, evaluate analytics, identify barriers/challenges, analyze performance improvement processes, and identify opportunities for future research.

Based on positive results of the KRYSTAL-1 clinical trial, adagrasib was granted accelerated FDA approval for patients with non–small-cell lung cancer harboring the KRAS G12C mutation.

This groundbreaking study reveals how AI-enabled interventions have the potential to revolutionize patient navigation by reducing burnout, increasing capacity, and creating sustainable healthcare solutions tailored to individual patient needs.

With former President Joe Biden’s prostate cancer diagnosis being thrust onto the world’s stage, it is imperative that we use this as a teachable opportunity to educate people about the disease—and to highlight how oncology navigators make a difference in prostate cancer care.